Liposomes in cancer immunotherapy

Liposome Technology: Interactions of Liposomes with the Biological Milieu

Volumn , Issue , 2006, Pages 347-360

  Adamina, Michel ^a   Schumacher, Reto ^a   Spagnoli, Giulio C ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33748477453     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (44)

1. Woodruff MF, Nolan B. Preliminary observations on treatment of advanced cancer by injection of allogeneic spleen cells. Lancet 1963; 13:426.
2. de Vries E, Coebergh JW. Cutaneous malignant melanoma in Europe. Eur J Cancer 2004; 40:2355.
3. Van der Bruggen P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643.
4. Adamina M, Oertli D. Antigen specific active immunotherapy: lessons from the first decade. Swiss Med Wkly. In press.
5. Bolli M, Kocher T, Adamina M, et al. Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann Surg 2002; 236:785.
6. Dunn GP, et al. Cancer immunoediting: from immunosurveillance to tumour escape. Nat Immunol 2002; 3:991.
7. O’Hagan DT, et al. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2003; 2:727.
8. Rosenberg SA, et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998; 90:1894.
9. Oertli D, et al. Rapid induction of specific cytotoxic T lymphocytes against melanoma associated antigens by a recombinant vaccinia virus vector expressing multiple immunodominant epitopes and costimulatory molecules in vivo. Hum Gene Ther 2002; 13:569.
10. Zajac P, et al. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum Gene Ther 2003; 14:1497.
11. Parmiani G, et al. Cancer immunotherapy with peptide based vaccines: What have we achieved? Where are we going? J Nat Cancer Inst 2002; 94:805.
12. Rosenberg SA, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4:321.
13. Peterson AC, et al. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol 2003; 21:2342.
14. Weber J, et al. Granulocyte-macrophage colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer 2003; 97:186.
15. Cavazza A, et al. Hydrolysis of the tumor-associated antigen epitope gp100(280-288) by membrane-associated and soluble enzymes expressed by immature and mature dendritic cells. Clin Immunol 2004; 111.
16. Albo F, et al. Degradation of the tumor antigen epitope gp100(280-288) by fibroblast-associated enzymes abolishes specific immunorecognition. Biochim Biophys Acta 2004; 1671.
17. Blanchet JS, et al. A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implications for molecular anti-melanoma immunotherapy. J Immunol 2001; 167:5852.
18. Smith JW, et al. Adjuvant immunization of HLA-A2-positive melanoma patients with modified gp100 peptide induces peptide-specific CD8þ T-cell responses. J Clin Oncol 2003; 21:1562.
19. Adamina M, et al. Encapsulation into sterically stabilized liposomes improves the immunogenicity of melanoma associated Mart-1/Melan-A epitope. Br J Cancer 2004; 90:263.
20. Gluck R. Liposomal presentation of antigens for human vaccines. Pharm Biotechnol 1995; 6:325.
21. Alving CR, et al. Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Immunol Rev 1995; 145:5.
22. Gregoriadis G, et al. Vaccine entrapment in liposomes. Methods 1999; 19:156.
23. Shen Z, et al. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 1997; 158:2723.
24. Agrawal B, et al. Rapid induction of primary CD4þ and CD8þ T cell responses against cancer-associated MUC-1 peptide epitopes. Int Immunol 1998; 157:2089.
25. Senior J, Crawley JC, Gregoriadis G. Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection. Biochim Biophys Acta 1985; 839:1.
26. Oussoren C, Storm G. Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev 2001; 50:143.
27. Woodle MC, Lasic DD. Sterically stabilized liposomes. Biochim Biophys Acta 1992; 1113:171.
28. Allen TM. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci 1994; 15:215.
29. Ignatius R, et al. Presentation of proteins encapsulated in sterically stabilized liposomes by dendritic cells initiates CD8(þ) T-cell responses in vivo. Blood 2000; 96:3505.
30. Marchand M, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999; 80:219.
31. Coulie P, van der Bruggen P. T-cell responses of vaccinated cancer patients. Curr Opin Immunol 2003; 15:131.
32. Kawakami Y, et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2- restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180:347.
33. Valmori D, et al. Enhanced generation of specific tumor reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 1998; 160:1750.
34. Gervois N, et al. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions. J Exp Med 1996; 183:2403.
35. Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001; 106:263.
36. Jaeger E, et al. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma- associated antigens. Int J Cancer 1996; 66:162.
37. Thurner B, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocytederived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999; 190:1669.
38. Nestle FO, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4:328.
39. Zinkernagel RM, Hengartner H. Regulation of the immune response by antigen. Science 2001; 293:251.
40. Lasic DD. Novel applications of liposomes. Trends Biotechnol 1998; 16:307.
41. Ludewig B, et al. Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells. J Immunol 2001; 166:3678.
42. Neidhart J, et al. Immunization of colorectal cancer patients with recombinant baculovirus-derived KSA (Ep-CAM) formulated with monophosphoryl lipid A in liposomal emulsion, with and without granulocyte-macrophage colonystimulating factor. Vaccine 2004; 22:773.
43. Zinkernagel RM. Immunity against solid tumors? Int J Cancer 2001; 93:1.
44. Schild H, et al. Limit of T cell tolerance to self proteins by peptide presentation. Science 1990; 247:1587.